News | News By Subject | News by Disease News By Date | Search News

Cystic fibrosis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
FDA Spurns Vertex (VRTX) Application for Expanded Use of Kalydeco     2/5/2016
How Vertex (VRTX)'s Long-Term $500K Gamble Paid Off with a $30 Billion Return     11/18/2015
Vertex (VRTX)'s Success Spurs Startups Corbus and Pulmatrix to Enter Cystic Fibrosis Market     8/18/2015
Watch Out Gilead (GILD), Investors Feel Vertex (VRTX) May Be Biogen (BIIB)'s Good Fit     8/4/2015
Vertex (VRTX) Gets FDA Approval for $259K Per Year CF Drug     7/7/2015
Vertex (VRTX) Poised to Become Profitable Following Expected FDA Approval of Orkambi     7/1/2015
Tiny Parion Sciences Wrangles Lung Pact Worth $1.2 Billion From Vertex (VRTX)     6/8/2015
Corbus Will Interview Twice as Many Candidates in 2015 as Its Ranks Grow     5/29/2015
Your Analyst-Vetted Guide to the Five Blockbuster Drugs the FDA May Approve This Summer     5/28/2015
Vertex (VRTX) Soars After Hours as FDA Panel Backs Cystic Fibrosis Drug Orkambi     5/15/2015
Investors Hold Their Breath as Vertex (VRTX) Defends Newly Branded Cystic Fibrosis Treatment to the FDA     5/12/2015
Heart-Stopping Morning Leads to Vertex (VRTX) Rise As FDA News Sees Positives     5/11/2015
Tiny Corbus Looks to Give Vertex (VRTX) Some Competition With Experimental Cystic Fibrosis Drug     5/6/2015
Buy Vertex (VRTX) Now for $45B Or Risk It All, Analyst Tells Gilead (GILD)     4/27/2015
Here's Why Investors are Already Anticipating Vertex (VRTX) Trial Data Coming This Month     3/17/2015

News from Around the Web
Fast, Accurate Cystic Fibrosis Test Developed At Stanford University     2/2/2016
Why Investors Shouldn't Freak Out Over Vertex (VRTX)'s Latest Trial Results     3/24/2015
Garlic Could Help Cure Lung Infection, University of Edinburgh Study     2/25/2015
University of Pittsburgh-Led Study Suggests Cystic Fibrosis Is Two Diseases, One Doesn’t Affect Lungs     7/23/2014
Cystic Fibrosis And Diabetes Link Explained, Lund University Study     6/3/2014
New Drug Target Found for Cystic Fibrosis Lung Disease, BC Children's Hospital Study     11/8/2012
Sea Sponge Chemical Fixes Cystic Fibrosis Defect, McGill University Study     10/29/2012
Differences Seen in Lung Microbes of Cystic Fibrosis Patients, Stanford University Study     10/1/2012
Big Advance Against Cystic Fibrosis: Stem Cell Researchers Create Lung Surface Tissue in a Dish, Massachusetts General Hospital Study     4/6/2012
Student, 16, Invents New Drug Cocktail to Fight Cystic Fibrosis, Wins Canadian Biotech Challenge, National Research Council of Canada laboratories Reveals     5/12/2011
Cystic Fibrosis Patients May Benefit From Combination Therapy Which Provides Hope For Cure Of Dangerous Infections, McMaster University Study     4/25/2011
New Cystic Fibrosis Drug Improves Lung Function, University of Colorado Study     12/22/2010
Novel Drug Aids CF Kids' Lungs, University of Colorado Study     12/20/2010
Drug Corrects CF Genetic Defect, University of Colorado Reveals     11/18/2010
TOBI Reduces Mortality in Patients with Cystic Fibrosis, Pa Lung Infection, Children's Hospital Boston Study     10/22/2010

Press Releases
Vertex (VRTX) Reports Full-Year And Fourth Quarter 2015 Financial Results     1/28/2016
Vertex (VRTX) Release: Health Canada Approves PrORKAMBI (Lumacaftor/Ivacaftor) - The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis For People Ages 12 And Older With Two Copies Of The F508del Mutation     1/27/2016
PTC Therapeutics (PTCT) Outlines Business Priorities For The Development And Commercialization Of Translarna And Progress Of The Company Pipeline     1/11/2016
Nivalis Therapeutics Announces First Patient Dosed In Phase II Study Of N91115 For Treatment Of Cystic Fibrosis     12/1/2015
Proteostasis Therapeutics, Inc. Demonstrates Therapeutic Potential Of A Proprietary Triple Combination Therapy For The Treatment Of Cystic Fibrosis That Restores Activity Of Mutant F508del CFTR Protein To 80% Of Normal     11/23/2015
Vertex (VRTX) Receives EU Approval For ORKAMBI (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation     11/20/2015
PTC Therapeutics (PTCT) Completes Enrollment Of Phase 3 Clinical Trial Of Translarna For Patients With Cystic Fibrosis     11/19/2015
Vertex (VRTX) Receives Two EU Approvals For KALYDECO (ivacaftor) For People With Cystic Fibrosis     11/18/2015
Concert Pharmaceuticals, Inc. (CNCE) Initiates Phase 1 Multiple Ascending Dose Trial With CTP-656 For Cystic Fibrosis     11/12/2015
Concert Pharmaceuticals, Inc. (CNCE) Reports Third Quarter 2015 Financial Results And Provides Company Update     11/5/2015
Vertex (VRTX) Reports Third Quarter 2015 Financial Results     10/29/2015
OrPro Therapeutics Receives US Patent Covering Novel Enzymatic Treatment for Cystic Fibrosis     10/27/2015
Corbus Announces FDA Orphan Drug Designation And Fast Track Status Of ResunabFor The Treatment Of Cystic Fibrosis     10/20/2015
Corbus Announces First Patient Dosed In Phase 2 Study Of Resunab For Treatment Of Cystic Fibrosis     10/15/2015
Aradigm Corporation (ARDM) Completes Enrollment In The Second Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)     10/13/2015